FR2878160B1 - Utilisation du n-acetyl-taurinate de magnesium pour la preparation de medicaments inhibiteurs de l'hypersensiblite photique - Google Patents

Utilisation du n-acetyl-taurinate de magnesium pour la preparation de medicaments inhibiteurs de l'hypersensiblite photique

Info

Publication number
FR2878160B1
FR2878160B1 FR0412292A FR0412292A FR2878160B1 FR 2878160 B1 FR2878160 B1 FR 2878160B1 FR 0412292 A FR0412292 A FR 0412292A FR 0412292 A FR0412292 A FR 0412292A FR 2878160 B1 FR2878160 B1 FR 2878160B1
Authority
FR
France
Prior art keywords
hypersensiblity
photic
magnesium
preparation
inhibitory drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR0412292A
Other languages
English (en)
Other versions
FR2878160A1 (fr
Inventor
Jean Pierre Durlach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to FR0412292A priority Critical patent/FR2878160B1/fr
Publication of FR2878160A1 publication Critical patent/FR2878160A1/fr
Application granted granted Critical
Publication of FR2878160B1 publication Critical patent/FR2878160B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR0412292A 2004-11-19 2004-11-19 Utilisation du n-acetyl-taurinate de magnesium pour la preparation de medicaments inhibiteurs de l'hypersensiblite photique Active FR2878160B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR0412292A FR2878160B1 (fr) 2004-11-19 2004-11-19 Utilisation du n-acetyl-taurinate de magnesium pour la preparation de medicaments inhibiteurs de l'hypersensiblite photique

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0412292A FR2878160B1 (fr) 2004-11-19 2004-11-19 Utilisation du n-acetyl-taurinate de magnesium pour la preparation de medicaments inhibiteurs de l'hypersensiblite photique

Publications (2)

Publication Number Publication Date
FR2878160A1 FR2878160A1 (fr) 2006-05-26
FR2878160B1 true FR2878160B1 (fr) 2008-07-25

Family

ID=34952851

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0412292A Active FR2878160B1 (fr) 2004-11-19 2004-11-19 Utilisation du n-acetyl-taurinate de magnesium pour la preparation de medicaments inhibiteurs de l'hypersensiblite photique

Country Status (1)

Country Link
FR (1) FR2878160B1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1025645B1 (fr) * 2017-10-13 2019-05-15 Synapharm Industrial Synthesis Compose pour le traitement de la neurotoxicite due a l'hyperexcitabilite des recepteurs glutamatergiques ionotropes
BR112023026487A2 (pt) * 2021-06-15 2024-03-05 Celagenex Res India Pvt Ltd Composição sinérgica para inibir calcificação vascular

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2384751A1 (fr) * 1977-03-23 1978-10-20 Francaise Coop Pharma Nouveaux derives de la taurine a activite neuro-musculaire renforcee
US5460972A (en) * 1991-04-08 1995-10-24 Research Foundation Of The State University Of New York Ionized magnesium2+ concentrations in biological samples

Also Published As

Publication number Publication date
FR2878160A1 (fr) 2006-05-26

Similar Documents

Publication Publication Date Title
FR20C1048I2 (fr) Utilisation du désoxycholate de sodium pour l' élimination non chirurgicale de graisse
FR2867778B1 (fr) Utilisation de derives d'indazolecarboxamides pour la preparation d'un medicament destine au traitement et a la prevention du paludisme
FR15C0046I2 (fr) Medicaments pour le traitement ou la prevention de maladies fibrotiques
IL176629A0 (en) Sulfonamide derivatives for the treatment of diseases
AP2006003669A0 (en) Sulfonamide derivatives for the treatment of diseases
FR13C0029I2 (fr) Compositions pour le traitement de troubles gastro-intestinaux
FR2854074B1 (fr) Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
FR2879914B1 (fr) Ecarteur-retenteur d'intestins pour chirurgie coelioscopique
FR2860154B1 (fr) Composition pour le traitement de la mauvaise haleine
FR2873294B1 (fr) Association de medicaments
FR2873926B1 (fr) Composition pour la reduction des lipides sanguins
FR2878160B1 (fr) Utilisation du n-acetyl-taurinate de magnesium pour la preparation de medicaments inhibiteurs de l'hypersensiblite photique
PL1637165T3 (pl) Medyczna emulsja chłodząca
FR2883180B1 (fr) Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
MA28513B1 (fr) Processus pour la preparation d'inhibiteurs de tryptase
FR2896690B1 (fr) Utilisation de l'enantiomere(s) de la mequitazine pour la preparation d'un medicament, tout en limitant la toxicite genomique
FR2849599B1 (fr) Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete
FR2837707B1 (fr) Utilisation de la 8'-hydroxydihydroergotamine pour un medicament anxiolytique
FR2866570B1 (fr) Utilisation du metronidazole pour la preparation d'une composition pharmaceutique destinee a traiter une inflammation cutanee
FR2881655B3 (fr) Preparation d'aldesleukine pour une utilisation pharmaceutique
FR2908652B1 (fr) Utilisation d'ethoxuquine pour le traitement de la canitie
FR2866568B1 (fr) Utilisation du metronidazole pour la preparation d'une composition pharmaceutique destinee a traiter un desordre de la vascularisation cutanee
UA10726S (uk) Комплект упаковок для фармацевтичного препарату «дермазол»
ITSV20040008A1 (it) Dottor "g"
IL176564A0 (en) Sulfonamide derivatives for the treatment of diseases

Legal Events

Date Code Title Description
TP Transmission of property
PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19